TRIMTECH extends seed round to $47M for protein degradation drugs

Why it matters: The biotech from Cambridge is developing small molecule drugs designed to degrade toxic protein aggregates linked to neurodegenerative diseases – a notoriously difficult area where many therapies have failed.

What’s new: The seed extension was led by Johnson & Johnson Innovation, the corporate venture capital arm of Johnson & Johnson, and BGF. They join existing investors Cambridge Innovation Capital, Dementia Discovery Fund, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures and Start Codon.

How it works: TRIMTECH is building drug candidates based on TRIM21, an E3 ligase involved in protein degradation.

• The company says its TRIMTAC and TRIMGLUE platforms can selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of the same proteins intact.
• That distinction matters because many neurodegenerative diseases are associated with misfolded or aggregated proteins, but fully removing a protein can interfere with its normal biological function.

What they’re saying: “This additional funding allows us to forge ahead with developing our portfolio of CNS penetrant degraders based on our unique platforms,” TRIMTECH CEO Nicola Thompson said in a statement.

Backstory: TRIMTECH was founded in 2023 by Leo James of the MRC Laboratory of Molecular Biology and Will McEwan of the UK Dementia Research Institute at the University of Cambridge, alongside Cambridge Innovation Capital and Dementia Discovery Fund. The company previously announced a $31 million seed round in 2025.

Yes, but: TRIMTECH has not disclosed a lead indication, lead target, development timeline or when it expects to enter the clinic.

What we’re watching: Most targeted protein degradation companies have focused first on oncology or immunology, where targets, biomarkers and clinical readouts are usually more straightforward, but neuroscience interest is building.

• France’s Ipsen recently partnered with U.S.-based Origami Therapeutics on a small molecule protein degrader programme for a rare inherited neurodegenerative disorder.
• U.S.-based Arvinas is working on PROTAC degraders for mutant huntingtin, tau and alpha-synuclein – three proteins linked to Huntington’s, Alzheimer’s and Parkinson’s disease.